VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
... targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis. A ... of inflammation and inflammatory processes in the vessel wall as a critical step in combating ... medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of ...Old and new therapies combine to tackle atherosclerosis
... fumagillin, a potent compound that stops blood vessel growth. "We saw that statins sustain the acute inhibition of blood vessel growth produced by the fumagillin nanoparticles ... be used to further inhibit the development of new vessel treatment in high-risk patients, Lanza says. ...Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System
... Device Designed to Provide Fast, Safe and Secure vessel Closure Following ... SE Vascular Closure System, a next-generation vessel closure device engineered to enable fast, safe ... step leading to clip deployment -- Immediate vessel closure with deployment of a shape-memory clip ...JCI table of contents: April 22, 2008
... If a blood clot forms in an intact blood vessel it is known as a thrombus and it can have serious ... are released into the circulation when a blood vessel is injured. In the study, CD36 was shown to ... from the cells that would be damaged by blood vessel injury and to microparticles isolated from ...Nanosized technology has supersized effect on tumors
... So the nanoparticles latched on to sites of blood vessel proliferation and released their fumagillin load into blood vessel cells. Fumagillin blocks multiplication of blood vessel cells, so it inhibited tumors from expanding ...Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
... it has received 510(k) clearance for an important vessel wall detection technology from the U.S. Food and ... an important element of the System involved in vessel wall detection. The advanced technology will allow the System to sense the vessel wall farther in advance. ...VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
... drug that targets inflammation in the blood vessel wall, a primary disease process ... oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of ... medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of ...On the road to a new cancer therapy -- starving the tumor
... − often with deadly consequences. Blood vessel formation (or angiogenesis) Every developing ... is supplied with nutrients. Curbing blood vessel formation as a treatment for cancer Peter ... or PLGF. Oddly enough, PLGF only stimulates blood vessel formation in cancer and other diseases, but not ...AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
... designed to embolize, or close blood vessel and blood vessel malformations in the peripheral ... to 22 mm enabling treatment of a wider range of vessel sizes. Unlike competing devices, a single ... II is generally required to occlude the targeted vessel making it a cost and time effective alternative. ...FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
... (R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS ... and deliverability advantages. Additionally, in the TAXUS Atlas Small vessel clinical trial, the TAXUS Liberte Atom Stent yielded a two-year target ...Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
... Inc. ("Prospect"). In preclinical studies, GCS-100 inhibited blood vessel formation in a variety of cancer models. Development and growth of solid tumors requires new blood vessel growth, or angiogenesis, to deliver oxygen and nutrients to a tumor. ...The Importance of Mixing: How to Compare Lab Scale Mixing with Full Scale Process Vessel Performance
... of Mixing: How to Compare Lab Scale Mixing with Full Scale Process vessel Performance . Process objectives are critical for successful ... a lab reactor compares to the mixing performance of a full scale process vessel which is targeted to receive the lab developed process. Your webinar ...VIA Pharmaceuticals Secures Financing Up to $10.0 Million
... disease caused by atherosclerosis, by targeting inflammation in the blood vessel wall, an underlying cause of atherosclerosis," said Lawrence K. Cohen, ... a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its ...Boston Scientific Acquires Labcoat Limited
... to significantly reduce the amount of polymer and drug to which the vessel wall is exposed, while minimizing polymer and drug on the inner surface of ... as a conventional drug-eluting stent, but faster and more complete vessel healing after stent implantation. "Boston Scientific has enjoyed an ...OmegaGenesis Announces Angiogenesis Application Collaboration
... and resulting products to market based on the idea that controlling blood vessel growth would improve human body management for a diverse set of medical ... level -- accelerating cellular-based biologic therapies to control blood vessel growth. These nano-materials will enable doctors to treat disease at ...Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
... that two Maquet products, Vasoview(R) 6 and Vasoview(R) 7 Endoscopic vessel Harvesting Systems, infringe a patent for which Terumo CVS owns the rights ... ) Terumo CVS sells the VirtuoSaph(TM) Endoscopic vessel Harvesting System in the United States. The VirtuoSaph system is ...Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
... at two years. XIENCE V demonstrated a 32 percent reduction in target vessel failure (TVF, cardiac events related to the stented vessel) compared to ... Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products. About Abbott Abbott is a ...FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
... as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR). In May 2008, Abbott presented two-year data ... Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products. About Abbott Abbott is a ...On the boil: New nano technique significantly boosts boiling efficiency
... forest of nanorods "feed" nanobubbles into the microscale cavities of the vessel surface and help to prevent them from getting flooded with water. This ... transfer, in that it moves energy from a heat source to the bottom of a vessel and into the contained liquid, which then boils, and turns into vapor that ...Cardium Launches New AWARE Clinical Study Website
... Generx is designed to promote angiogenesis, a natural process of blood vessel growth within the heart muscle, following a one-time intracoronary ... however, including those with recurrent angina, coronary collateral vessel formation is insufficient to meet the heart's needs during stress. ...Paloma Pharmaceuticals to Present at the American Association for Cancer Research
... growth factors in excess of the angiogenic inhibitors, thus favoring blood vessel growth. Cancer cell induced angiogenesis utilizes common pathways of angiogenesis observed during normal vessel growth. Angiogenic factors pass from the cancer cell to the normal ...William Garland Joins AngioGenex's New Board of Directors
... degeneration. Others have demonstrated that blocking blood vessel formation is useful to treat some tumors in humans for which there are ... community to play an indispensable role in the creation of the new blood vessel networks that cancers need to grow and spread," according to ...Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in World's Largest Stent Registry
... percent), and TAXUS Liberte stent related re-intervention of the target vessel (2.5 percent). The one-year stent thrombosis rate was 0.8 percent, which ... were available for evaluation at one year. Patients with a single vessel treated with only one TAXUS Liberte stent were considered simple use ...